25346-09-2Relevant academic research and scientific papers
METHODS OF TREATING FRAGILE X SYNDROME, DOWN?S SYNDROME, AUTISM AND RELATED DISORDERS
-
, (2012/02/01)
Disclosed herein are methods of treating fragile X syndrome, fragile X-associated tremor/ataxia syndrome, Down?s syndrome and other forms of mental retardation, and/or autism comprising administering a GABA B agonist prodlug to a subject suffering therefrom. The GABAB agonist prodrugs can be compounds of Formula (I), (II) or (III) as disclosed herein
Use of GABA and GABAB agonists
-
, (2008/06/13)
The present invention provides methods of stimulating tissue growth, including islet cell growth, by administering GABA or a GABA agonist to act on GABAB receptors and GABAB-like receptors to activate cell replication.
A study of 3-amino-N-hydroxypropanesulfonamide derivatives as potential GABA(B) agonists and their fragmentation to 3-aminopropanesulfinic acid
Shue, Ho-Jane,Chen, Xiao,Blythin, David J.,Carruthers, Nicholas I.,Spitler, James M.,Wong, Shing-Chun,Chapman, Richard W.,Rizzo, Charles,West, Robert,She, Hoyan S.
, p. 1709 - 1714 (2007/10/03)
A series of 3-amino-N-hydroxypropanesulfonamide analogs were prepared. Several compounds showed potent binding at the GABA(B) receptor and were active in an in vitro functional assay. The GABA(B) activity of these compounds appeared to be due to the fragmented product, 3-aminopropanesulfinic acid.
